Taiho Pharmaceutical Co Ltd - Company Profile
Powered by 
All the data and insights you need on Taiho Pharmaceutical Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Taiho Pharmaceutical Co Ltd Strategy Report
- Understand Taiho Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Taiho Pharmaceutical Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Taiho Pharmaceutical Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 21 Feb 2020 | Lorem |
| AB Science’s masitinib has diminished Phase II/III success potential for 3L/4L CRC due to unclear value of available data, later-line efficacy challenges, experts say | 20 Dec 2018 | Reynald Castaneda |
| FGF-R valuable target for cholangiocarcinoma but no clear front runner amongst inhibitors under investigation; edge needed in small market, experts say | 17 Jul 2018 | Reynald Castaneda |
| BridgeBio’s Phase II infigratinib trial for cholangiocarcinoma enrols 75-80% of 120 patients, sources say | 11 Jul 2018 | Reynald Castaneda |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer